CD141 Monoclonal Antibody (LS17-9), Brilliant Ultra Violet™ 805, eBioscience™, Invitrogen™

Description

The monoclonal antibody LS17-9 recognizes mouse CD141, a type I cell surface glycoprotein that binds to and allosterically activates thrombin. This complex cleaves protein C and the Thrombin Activatable Fibrinolysis Inhibitor (TAFI), initiating an important anticoagulant and antifibrinolytic pathway. Although expressed across many tissues and cell types, its highest expression has been reported on the lumenal surface of vascular endothelial cell. In the immune system the highest expression can be observed on monocytes and macrophages. Soluble CD141 is constitutively present in the serum at a very low level, and can be upregulated during inflammation. The anti-inflammatory activity of CD141 results from its ability to block the highly pro-inflammatory activity of thrombin. CD141 prevents chemotaxis and binding of granulocytes to activated endothelium, and inhibits activation of eosinophils and mast cells thereby reducing inflammation. Although human CD141 is commonly used as a marker of cross-presenting dendritic cells, mouse CD141 does not exhibit the same expression pattern. This LS17-9 antibody has been reported for use in flow cytometric analysis. This LS17-9 antibody has been tested by flow cytometric analysis of mouse resident peritoneal macrophages. This may be used at less than or equal to 0.25 μg per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Brilliant Ultraviolet 805 is a tandem dye that emits at 797 nm.